Arvinas, Inc. ARVN
7.09 USD -0.43 (-5.72%)
At closeNov 3, 2026, 4:01 PM EST
7.09 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
6.79 Day range 7.73
6.74 52-week range 14.51
- YTD
- -40.22%
- 1 year
- -27.06%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 58.55 +725.8% upside
Now 7.09
- Target (low)
- 19.00
- Target (mean)
- 58.55
- Target (high)
- 110.00
Ratings (0m) 22 19 buy · 3 hold · 0 sell
- Strong buy5
- Buy14
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 22
- 1 month ago 22
- 2 months ago 22
- 3 months ago 22
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.02 | -1.58 – -0.32 | -0.97 | -4.8% | 42.71M | +68.8% | 15 |
| Next quarter | -1.09 | -1.61 – -0.45 | -0.49 | -121.5% | 42.65M | -44.2% | 15 |
| Current year | -3.82 | -5.71 – -2.07 | -2.77 | -38.0% | 211.27M | -19.8% | 17 |
| Next year | -4.12 | -6.89 – 0.3234 | -3.82 | -7.9% | 236.17M | +11.8% | 18 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 11, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 7, 2025 | Citigroup | Maintained | Neutral | Neutral |
| Feb 12, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Feb 12, 2025 | BMO Capital | Reiterated | Outperform | Outperform |
| Feb 12, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Feb 12, 2025 | Stifel | Maintained | Buy | Buy |
| Feb 7, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Feb 3, 2025 | Barclays | Maintained | Overweight | Overweight |
| Dec 12, 2024 | Guggenheim | Reiterated | Buy | Buy |
| Dec 11, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 20, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Nov 18, 2024 | Stephens & Co. | Initiated | — | Overweight |
| Oct 31, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 31, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 9, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Aug 1, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 31, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Jul 31, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Jul 31, 2024 | Barclays | Maintained | Overweight | Overweight |
| Jul 31, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| May 17, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 9, 2024 | Wells Fargo | Maintained | Overweight | Overweight |
| May 8, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| May 8, 2024 | Stifel | Maintained | Buy | Buy |
| May 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 15, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 12, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 25, 2024 | Truist Securities | Reiterated | Buy | Buy |
| Feb 29, 2024 | Barclays | Maintained | Overweight | Overweight |
| Feb 28, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |